<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; Front Lines of TB R&amp;D</title>
	<atom:link href="http://www.newtbdrugs.org/blog/category/tb-research/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.newtbdrugs.org/blog</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Fri, 03 Feb 2012 22:43:04 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>TB R&amp;D Weekly Update:  Tailoring TB Treatment Based on Host Genotype?</title>
		<link>http://www.newtbdrugs.org/blog/2012/02/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/</link>
		<comments>http://www.newtbdrugs.org/blog/2012/02/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 22:40:47 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Life Cycle of Tuberculosis]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[host-targeting]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[zebra fish]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3466</guid>
		<description><![CDATA[This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2012/02/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  TDR Tuberculosis Strain Bank</title>
		<link>http://www.newtbdrugs.org/blog/2012/01/tb-rd-weekly-update-tdr-tuberculosis-strain-bank/</link>
		<comments>http://www.newtbdrugs.org/blog/2012/01/tb-rd-weekly-update-tdr-tuberculosis-strain-bank/#comments</comments>
		<pubDate>Fri, 20 Jan 2012 21:02:08 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Early Drug Development]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Diagnostics]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[research tool]]></category>
		<category><![CDATA[resource]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[TDR]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3420</guid>
		<description><![CDATA[This week we highlight an article looking at the TDR Tuberculosis Strain Bank and its utility.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2012/01/tb-rd-weekly-update-tdr-tuberculosis-strain-bank/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Dr. Yossef Av-Gay</title>
		<link>http://www.newtbdrugs.org/blog/2011/12/tb-rd-weekly-update-podcast-interview-with-dr-yossef-av-gay/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/12/tb-rd-weekly-update-podcast-interview-with-dr-yossef-av-gay/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:14:50 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Early Drug Development]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3378</guid>
		<description><![CDATA[This week we interview Dr. Yossef Av-Gay and discuss his recently published paper, his contribution to TB drug discovery and the focus of his research.  Dr. Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in PNAS that provides evidence to that points to a specific protein that allows Mtb to bypass the body's defenses.  Additional TB R&#038;D news links are included. ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/12/tb-rd-weekly-update-podcast-interview-with-dr-yossef-av-gay/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>4th Annual G-FINDER Survey Released</title>
		<link>http://www.newtbdrugs.org/blog/2011/12/4th-annual-g-finder-survey-released/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/12/4th-annual-g-finder-survey-released/#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:48:17 +0000</pubDate>
		<dc:creator>Heather_Ignatius</dc:creator>
				<category><![CDATA[Action]]></category>
		<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[global fund]]></category>
		<category><![CDATA[pdp]]></category>
		<category><![CDATA[policy]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[product development]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3364</guid>
		<description><![CDATA[Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released.  This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients--donors must commit to taking them across the finish line.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/12/4th-annual-g-finder-survey-released/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update: Tyrosine Kinases as Therapeutic Targets against TB</title>
		<link>http://www.newtbdrugs.org/blog/2011/11/tb-rd-weekly-update-tyrosine-kinases-as-therapeutic-targets-against-tb/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/11/tb-rd-weekly-update-tyrosine-kinases-as-therapeutic-targets-against-tb/#comments</comments>
		<pubDate>Wed, 30 Nov 2011 22:48:19 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[host]]></category>
		<category><![CDATA[host-targeting]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3346</guid>
		<description><![CDATA[This week's article looks at host factors that contribute to the ability of Mycobacterium tuberculosis (Mtb) to enter and survive within macrophages.  The authors explore the role of tyrosine kinases (TKs) as a mediator for Mtb and the use of an inhibitor of TKs to act against Mtb and related bacteria.  Additional links to TB R&#038;D news is included]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/11/tb-rd-weekly-update-tyrosine-kinases-as-therapeutic-targets-against-tb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast interview with Dr. Gyanu Lamicchane</title>
		<link>http://www.newtbdrugs.org/blog/2011/11/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/11/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/#comments</comments>
		<pubDate>Tue, 08 Nov 2011 21:47:25 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[JHU]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3325</guid>
		<description><![CDATA[Microbial geneticist Dr.  Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years.  In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane's motivation to work with TB.  Additional links to TB R&#038;D news are included.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/11/tb-rd-weekly-update-podcast-interview-with-dr-gyanu-lamicchane/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>International TB Research Roadmap Launched!</title>
		<link>http://www.newtbdrugs.org/blog/2011/11/international-tb-research-roadmap-launched/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/11/international-tb-research-roadmap-launched/#comments</comments>
		<pubDate>Thu, 03 Nov 2011 19:52:00 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3309</guid>
		<description><![CDATA[A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on Saturday at the Union World Conference on Lung Health.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/11/international-tb-research-roadmap-launched/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Zinc Used by Host to Fight TB</title>
		<link>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-zinc-used-by-host-to-fight-tb/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-zinc-used-by-host-to-fight-tb/#comments</comments>
		<pubDate>Tue, 20 Sep 2011 18:47:17 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Life Cycle of Tuberculosis]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[france]]></category>
		<category><![CDATA[Johns Hopkins]]></category>
		<category><![CDATA[networks]]></category>
		<category><![CDATA[nih/niaid]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3205</guid>
		<description><![CDATA[This week, we provide an brief overview of research supported by CNRS, INSERM, Institut Pasteur and other donors providing new evidence of the role of Zinc in the body's immune response to intracellular infection by M.tb. and the microbe's strategy to subvert this defense. Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-zinc-used-by-host-to-fight-tb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  TB Drug Updates in Future Medicinal Chemistry</title>
		<link>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-tb-drug-updates-in-future-medicinal-chemistry/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-tb-drug-updates-in-future-medicinal-chemistry/#comments</comments>
		<pubDate>Thu, 08 Sep 2011 21:23:32 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[india]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3140</guid>
		<description><![CDATA[Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases.  Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-tb-drug-updates-in-future-medicinal-chemistry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Future Medicinal Chemistry Features Neglected Diseases</title>
		<link>http://www.newtbdrugs.org/blog/2011/08/tb-rd-weekly-update-future-medicinal-chemistry-features-neglected-diseases/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/08/tb-rd-weekly-update-future-medicinal-chemistry-features-neglected-diseases/#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:57:14 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[neglected diseases]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3105</guid>
		<description><![CDATA[The August and September issues of Future Medicinal Chemistry will focus on neglected diseases including tuberculosis.  The issue includes articles from TB researchers including Ann Ginsberg and  Takushi Kaneko.  Additional links to TB R&#038;D news are included]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/08/tb-rd-weekly-update-future-medicinal-chemistry-features-neglected-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

